Ninety One North America Inc. Boosts Stock Position in Icon Plc $ICLR

Ninety One North America Inc. raised its holdings in Icon Plc (NASDAQ:ICLR) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 455,399 shares of the medical research company’s stock after acquiring an additional 12,552 shares during the period. Icon comprises about 3.4% of Ninety One North America Inc.’s investment portfolio, making the stock its 8th largest holding. Ninety One North America Inc.’s holdings in Icon were worth $82,983,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the business. WINTON GROUP Ltd acquired a new stake in shares of Icon during the second quarter worth about $254,000. Daiwa Securities Group Inc. lifted its holdings in shares of Icon by 19.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 28,145 shares of the medical research company’s stock valued at $4,094,000 after purchasing an additional 4,546 shares in the last quarter. Frontier Capital Management Co. LLC grew its position in shares of Icon by 97.6% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 71,360 shares of the medical research company’s stock valued at $10,379,000 after purchasing an additional 35,253 shares during the period. Peapack Gladstone Financial Corp bought a new stake in Icon during the 2nd quarter worth approximately $212,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Icon by 58.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company’s stock worth $113,000 after purchasing an additional 289 shares in the last quarter. 95.61% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

ICLR has been the topic of several research analyst reports. Robert W. Baird set a $119.00 target price on shares of Icon in a report on Friday, February 13th. Bank of America reiterated an “underperform” rating and issued a $75.00 price target on shares of Icon in a report on Thursday, February 12th. Jefferies Financial Group set a $135.00 price objective on shares of Icon and gave the stock a “buy” rating in a research report on Monday, February 23rd. Rothschild & Co Redburn set a $100.00 price objective on shares of Icon and gave the company a “neutral” rating in a research report on Tuesday, February 17th. Finally, Leerink Partners reaffirmed a “market perform” rating and issued a $105.00 target price on shares of Icon in a research note on Thursday, February 12th. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, Icon presently has an average rating of “Hold” and an average price target of $148.80.

Icon Stock Up 3.5%

ICLR stock opened at $119.68 on Friday. The company has a market cap of $9.67 billion, a price-to-earnings ratio of 16.19, a P/E/G ratio of 2.92 and a beta of 1.28. Icon Plc has a twelve month low of $66.57 and a twelve month high of $211.00. The business has a 50 day moving average price of $106.71 and a two-hundred day moving average price of $154.03. The company has a quick ratio of 1.06, a current ratio of 1.06 and a debt-to-equity ratio of 0.31.

About Icon

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.